Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | LPL | P06858 | 3/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17835050 | 0.94 | ENPP2 (0.52) | CA2ENPP2CA1MAPTKDR | |
| SCHEMBL2561437 | 0.90 | CA2 (0.55) | CA2ENPP2CA1MAPTLPL | |
| SCHEMBL13299302 | 0.87 | CA2 (0.52) | CA2ENPP2CA1KDRLPL | |
| SCHEMBL7821715 | 0.86 | LTA4H (0.45) | CA2ENPP2CA1KDRLPL | |
| SCHEMBL7334085 | 0.84 | ENPP2 (0.48) | CA2ENPP2CA1 | |
| SCHEMBL7334346 | 0.84 | ENPP2 (0.48) | CA2ENPP2CA1 | |
| SCHEMBL2559249 | 0.84 | CA1 (0.47) | CA2ENPP2CA1MAPTKDR | |
| SCHEMBL15067303 | 0.83 | CA1 (0.50) | CA2ENPP2CA1LPLLIPG | |
| SCHEMBL8339774 | 0.82 | MAPT (0.52) | MAPTKDM4ERECQLRAB9A | |
| SCHEMBL623764 | 0.82 | CA1 (0.57) | CA2ENPP2CA1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232090-A | 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2022-10-25 | — | — | CN | claimed |
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025228828-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES | MERCK PATENT GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-3920912-B1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-06-05 | — | — | US | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119841806-A | Polysubstituted quinazoline compound, preparation method, application and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2025-04-18 | — | — | CN | disclosed |
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1123296-B1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-6566381-B1 | For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | disclosed |
| EP-1165530-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6333330-B1 | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-12-25 | — | — | US | disclosed |
| US-6265606-B1 | TO CONTROL A BROAD SPECTRUM OF UNDESIRABLE VEGETATION, ARE SELECTIVE TO MAJOR CROPS, HAVE DESIRABLE ENVIRONMENTAL PROFILES, | DOW AGROSCIENCES LLC | 2001-07-24 | — | — | US | disclosed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| US-6010981-A | 1-alkyl-4-benzoyl-5-hydroxypyrazole compounds and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0914317-A2 | 1-ALKYL-4-BENZOYL-5-HYDROXYPYRAZOLE COMPOUNDS AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998052926-A2 | 1-ALKYL-4-BENZOYL-5-HYDROXYPYRAZOLE COMPOUNDS AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | CA2 4155/4885ENPP2 2410/4885CA1 4753/4885 |
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, PPIP5K2, IP6K1 | CA2 3051/4885ENPP2 465/4885CA1 3838/4885 |
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | ADAM9, ADAM17, ADAM8 | CA2 633/4885ENPP2 301/4885CA1 611/4885 |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | SLC2A9, SLC2A1, SLC2A8 | CA2 1142/4885ENPP2 448/4885CA1 3286/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | CA2 2456/4885ENPP2 369/4885CA1 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.